• Age ≥ 18 years old, regardless of gender;

• Malignant tumor patients diagnosed through pathological or cytological examination, regardless of cancer type, may experience thrombocytopenia during radical synchronous radiotherapy and chemotherapy treatment;

• Platelet count of patients ≤ 75 × 10\^9/L on the day or 3 days prior to enrollment;

• Expected survival time ≥ 12 weeks;

• ECOG PS score for physical condition: 0-2 points;

• The laboratory inspection indicators meet the following requirements:

‣ Renal function: Cr ≤ ULN (upper limit of normal value) x 1.5, endogenous creatinine clearance rate (Ccr) ≥ 55 ml/min;

⁃ Liver function: Total bilirubin ≤ ULN × 1.5; ALT and AST ≤ ULN × 3; (If it is intrahepatic cholangiocarcinoma or liver metastasis, total bilirubin should not exceed 3 times the normal upper limit, and transaminase should not exceed 5 times the normal upper limit);

• Women of childbearing age agree to use contraception during the study period and within 6 months after the end of the study; And not a lactating patient; Male patients who agree to contraception during the study period and within 6 months after the end of the study;

• Those who have not participated in clinical trials of other drugs within the 4 weeks prior to enrollment;

• It is expected that those with good compliance will be able to follow up on therapeutic effects and adverse reactions according to the protocol requirements;

• No serious complications such as active gastrointestinal bleeding, perforation, jaundice, gastrointestinal disorders Obstruction, non cancerous fever\>38 °C;

• The subjects are able to understand the situation of this study and voluntarily sign an informed consent form.